Government-Owned Inventions; Availability for Licensing, 31511 [2023-10485]
Download as PDF
<![CDATA[
Federal Register / Vol. 88, No. 95 / Wednesday, May 17, 2023 / Notices
Dated: May 11, 2023.
Miguelina Perez,
Program Analyst, Office of Federal Advisory
Committee Policy.
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
[FR Doc. 2023–10453 Filed 5–16–23; 8:45 am]
National Institute of General Medical
Sciences; Notice of Closed Meeting
BILLING CODE 4140–01–P
ddrumheller on DSK120RN23PROD with NOTICES1
Pursuant to section 1009 of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
General Medical Sciences Special Emphasis
Panel; Review of K99 MOSAIC Applications.
Date: June 13, 2023.
Time: 10:30 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
National Institute of General Medical
Sciences, Natcher Building, 45 Center Drive,
Bethesda, Maryland 20892 (Virtual Meeting).
Contact Person: Tracy Koretsky, Ph.D.
Scientific Review Officer, National Institute
of General Medical Sciences, National
Institutes of Health, 45 Center Drive, MSC
6200, Room 3AN12F, Bethesda, Maryland
20892, 301–594–2886, tracy.koretsky@
nih.gov.
Name of Committee: National Institute of
General Medical Sciences, Special Emphasis
Panel; Review of Applications of NRSA
Institutional Postdoctoral Training Grant
(T32).
Date: July 6, 2023.
Time: 9:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
National Institute of General Medical
Sciences, Natcher Building, 45 Center Drive,
Bethesda, Maryland 20892 (Virtual Meeting).
Contact Person: Lee Warren Slice, Ph.D.,
Scientific Review Officer, Office of Scientific
Review, National Institute of General Medical
Sciences, National Institutes of Health, 45
Center Drive, Room 3AN12, Bethesda,
Maryland 20892, 301–435–0807, slicelw@
mail.nih.gov.
Information is also available on the
Institute’s/Center’s home page:
www.nigms.nih.gov/, where an agenda and
any additional information for the meeting
will be posted when available.
(Catalogue of Federal Domestic Assistance
Program No. 93.859, Biomedical Research
and Research Training, National Institutes of
Health, HHS)
VerDate Sep<11>2014
18:34 May 16, 2023
Jkt 259001
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions;
Availability for Licensing
AGENCY:
National Institutes of Health,
HHS.
ACTION:
Notice.
The invention listed below is
owned by an agency of the U.S.
Government and is available for
licensing to achieve expeditious
commercialization of results of
federally-funded research and
development. Foreign patent
applications are filed on selected
inventions to extend market coverage
for companies and may also be available
for licensing.
FOR FURTHER INFORMATION CONTACT:
Licensing information may be obtained
by communicating with the Technology
Transfer and Intellectual Property
Office, National Institute of Allergy and
Infectious Diseases, 5601 Fishers Lane,
Rockville, MD 20852 by contacting Dr.
Benjamin Hurley at 240–669–5092 or
benjamin.hurley@nih.gov. A signed
Confidential Disclosure Agreement will
be required to receive copies of
unpublished information related to the
invention.
SUPPLEMENTARY INFORMATION:
Technology description follows:
SUMMARY:
Nanoparticle Vaccine Against Mpox
Description of Technology:
In 2022, the World Health
Organization declared an atypical
outbreak of monkeypox (Mpox), which
has caused approximately 30,000 cases
of Mpox infection within the United
States as of April 2023. Mpox represents
a current threat to public health, and
there is an immediate need for an
effective vaccine. To address this,
NIAID has developed a vaccine
approach comprising virus-like
nanoparticles coated with modified
Mpox proteins. NIAID investigations
have demonstrated that immunization
has elicited a robust immune response
in mice and provided protection against
a lethal infection of Vaccinia virus.
This technology is available for
licensing for commercial development
in accordance with 35 U.S.C. 209 and 37
PO 00000
Frm 00034
Fmt 4703
Sfmt 4703
31511
CFR part 404, as well as for further
development and evaluation under a
research collaboration.
Potential Commercial Applications:
• Immunization: Mpox nanoparticle
vaccines may be more effective than
current MVA vaccination approaches in
providing protection against Mpox
infection.
• The methodology for manufacturing
the Mpox nanoparticle vaccine could be
readily adapted to generate vaccines for
other poxviruses.
Competitive Advantages:
• A Mpox nanoparticle vaccine may
have fewer side effects than available
MVA based vaccines.
• The storage and transport
requirements of a Mpox nanoparticle
vaccine are better suited to low resource
settings than MVA vaccines.
Inventors: Bernard Moss, MD, Ph.D.
Publications: Publication pending.
Intellectual Property: HHS Reference
No. E–183–2022; U.S. Provisional
Application No. 63/402,702.
Licensing Contact: To license this
technology, please contact Benjamin
Hurley at 240–669–5092 or
benjamin.hurley@nih.gov, and reference
E–183–2022.
Collaborative Research Opportunity:
The National Institute of Allergy and
Infectious Diseases is seeking statements
of capability or interest from parties
interested in collaborative research to
further develop, evaluate, or
commercialize this invention. For
collaboration opportunities, please
contact Benjamin Hurley; 240–669–
5092, benjamin.hurley@nih.gov.
Dated: May 9, 2023.
Surekha Vathyam,
Deputy Director, Technology Transfer and
Intellectual Property Office, National Institute
of Allergy and Infectious Diseases.
[FR Doc. 2023–10485 Filed 5–16–23; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Center for Scientific Review; Notice of
Closed Meetings
Pursuant to section 1009 of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
E:\FR\FM\17MYN1.SGM
17MYN1
]]>Agencies
[Federal Register Volume 88, Number 95 (Wednesday, May 17, 2023)]
[Notices]
[Page 31511]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2023-10485]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions; Availability for Licensing
AGENCY: National Institutes of Health, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The invention listed below is owned by an agency of the U.S.
Government and is available for licensing to achieve expeditious
commercialization of results of federally-funded research and
development. Foreign patent applications are filed on selected
inventions to extend market coverage for companies and may also be
available for licensing.
FOR FURTHER INFORMATION CONTACT: Licensing information may be obtained
by communicating with the Technology Transfer and Intellectual Property
Office, National Institute of Allergy and Infectious Diseases, 5601
Fishers Lane, Rockville, MD 20852 by contacting Dr. Benjamin Hurley at
240-669-5092 or [email protected]. A signed Confidential
Disclosure Agreement will be required to receive copies of unpublished
information related to the invention.
SUPPLEMENTARY INFORMATION: Technology description follows:
Nanoparticle Vaccine Against Mpox
Description of Technology:
In 2022, the World Health Organization declared an atypical
outbreak of monkeypox (Mpox), which has caused approximately 30,000
cases of Mpox infection within the United States as of April 2023. Mpox
represents a current threat to public health, and there is an immediate
need for an effective vaccine. To address this, NIAID has developed a
vaccine approach comprising virus-like nanoparticles coated with
modified Mpox proteins. NIAID investigations have demonstrated that
immunization has elicited a robust immune response in mice and provided
protection against a lethal infection of Vaccinia virus.
This technology is available for licensing for commercial
development in accordance with 35 U.S.C. 209 and 37 CFR part 404, as
well as for further development and evaluation under a research
collaboration.
Potential Commercial Applications:
Immunization: Mpox nanoparticle vaccines may be more
effective than current MVA vaccination approaches in providing
protection against Mpox infection.
The methodology for manufacturing the Mpox nanoparticle
vaccine could be readily adapted to generate vaccines for other
poxviruses.
Competitive Advantages:
A Mpox nanoparticle vaccine may have fewer side effects
than available MVA based vaccines.
The storage and transport requirements of a Mpox
nanoparticle vaccine are better suited to low resource settings than
MVA vaccines.
Inventors: Bernard Moss, MD, Ph.D.
Publications: Publication pending.
Intellectual Property: HHS Reference No. E-183-2022; U.S.
Provisional Application No. 63/402,702.
Licensing Contact: To license this technology, please contact
Benjamin Hurley at 240-669-5092 or [email protected], and
reference E-183-2022.
Collaborative Research Opportunity: The National Institute of
Allergy and Infectious Diseases is seeking statements of capability or
interest from parties interested in collaborative research to further
develop, evaluate, or commercialize this invention. For collaboration
opportunities, please contact Benjamin Hurley; 240-669-5092,
[email protected].
Dated: May 9, 2023.
Surekha Vathyam,
Deputy Director, Technology Transfer and Intellectual Property Office,
National Institute of Allergy and Infectious Diseases.
[FR Doc. 2023-10485 Filed 5-16-23; 8:45 am]
BILLING CODE 4140-01-P
